Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis

Journal of Hepatology

Volumn 29, Issue 3, 1998, Pages 409-416

  Sasatomi, Kurumi ^a   Noguchi, Kazunori ^a   Sakisaka, Shotaro ^a   Sata, Michio ^a   Tanikawa, Kyuichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biliary epithelial cells; Confocal laser scanning microscope; Endotoxin; Lipid A; Primary biliary cirrhosis; Primary sclerosing cholangitis; Ursodeoxycholic acid

Indexed keywords

ENDOTOXIN; LIPID A; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONFOCAL LASER MICROSCOPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TOXIN ANALYSIS;

EID: 0032171526     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80058-5     Document Type: Article

References (37)

1. Nolan JP. Intestinal endotoxins as mediators of hepatic injury: an idea whose time has come again. Hepatology. 10:1989;887-891.
2. Ravin HA, Rowley D, Jenkins C, Fine J. On the absorption of bacterial endotoxin from the gastro-intestinal tract of the normal and shocked animal. J Exp Med. 112:1960;783-792.
3. Wolter J, Liehr H, Grun M. Hepatic clearance of endotoxins: differences in arterial and portal venous infusion. J Ret Soc. 23:1978;145-152.
4. Greve JWM, Gouma DJ, Buurman WA. Complications in obstructive jaundice: role of endotoxins. Scand J Gastroenterol. 194:1992;8-12. (Suppl).
5. Tachiyama G, Sakon M, Kambayashi J, Iijima S, Tsujinaka T, Mori T. Endogenous endotoxemia in patients with liver cirrhosis: a quantitative analysis of endotoxin in portal and peripheral blood. Jpn J Surg. 18:1988;403-408.
6. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology. 8:1988;232-236.
7. Yamamoto Y, Sezai S, Sakurabayashi S, Hirano M, Kamisaka K, Oka H. A study of endotoxaemia in patients with primary biliary cirrhosis. J Int Med Res. 22:1994;95-99.
8. Drivas G, James O, Wardle N. Study of reticuloendothelial phagocytic capacity in patients with cholestasis. Br Med J. 1:1976;1568-1569.
9. Mimura Y, Sakisaka S, Harada M, Sata M, Tanikawa K. Role of hepatocytes in direct clearance of lipopolysaccharide in rats. Gastroenterology. 109:1995;1969-1976.
10. Bailey ME. Endotoxin, bile salts and renal function in obstructive jaundice. Br J Surg. 63:1976;774-778.
11. Freudenberg MA, Freudenberg N, Galanos C. Time course of cellular distribution of endotoxin in liver, lungs and kidneys of rats. Br J Exp Pathol. 63:1982;56-65.
12. Bossuyt HV, Zanger RBD, Wisse E. Cellular and subcellular distribution of injected lipopolysaccharide in rat liver and its inactivation by bile salts. J Hepatol. 7:1988;325-337.
13. Nakao A, Taki S, Yasui M, Kimura Y, Nonami T, Harada A, et al. The fate of intravenously injected endotoxin in normal rats and in rats with liver failure. Hepatology. 19:1994;1251-1256.
14. Ruiter DJ, Van Der Meulen, Brouwer A, Hummel MJR, Mauw BJ, Van Der Ploeg JCM, et al. Uptake by liver cells of endotoxin following its intravenous injection. Lab Invest. 45:1981;38-45.
15. Freudenberg MA, Galanos C. Bacterial lipopolysaccharides: structure, metabolism and mechanisms of action. Intern Rev Immunol. 6:1990;207-221.
16. Wood DM, Parent JB, Gazzano-Santoro H, Lim E, Pruyne PT, Watkins JM, et al. Reactivity of monoclonal antibody E5 with endotoxin. I. Binding to lipid A and rough lipopolysaccharides. Circ Shock. 38:1992;55-62.
17. Parent JB, Gazzano-Santoro H, Wood DM, Lim E, Pruyne PT, Trown PW, et al. Reactivity of monoclonal antibody E5 with endotoxin. II. Binding to short- and long-chain smooth lipopolysaccharides. Circ Shock. 38:1992;63-73.
18. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multicenter doubleblind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 19:1994;1149-1156.
19. UDCA-PBC Study Group Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med. 330:1994;1342-1347.
20. Chazouillieres O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol. 11:1990;120-123.
21. Scheuer PJ. Primary biliary cirrhosis. Proc R Soc Med. 60:1967;1257-1260.
22. Sakisaka S, Watanabe M, Tateishi H, Harada M, Shakado S, Mimura Y, et al. Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia: immunohistochemical evidence. Hepatology. 18:1992;1357-1362.
23. Sakisaka S, Gondo K, Yoshitake M, Harada M, Sata M, Kobayashi K, et al. Functional differences between hepatocytes and biliary epithelial cells in handling polymeric immunoglobulin A2 in humans, rats, and guinea pigs. Hepatology. 24:1996;398-406.
24. Dodge DE, Rucker RB, Singh G, Plopper CG. Quantitative comparison of intracellular concentration and volume of clara cell 10 KD protein in rat bronchi and bronchioles based on laser scanning confocal microscopy. J Histochem Cytochem. 41:1993;1171-1183.
25. Lizard G, Chignol MC, Souchier C, Schmitt D, Chardonnet Y. Laser scanning confocal microscopy and quantitative microscopy with a charge coupled device camera improve detection of human papillomavirus DNA revealed by fluorescence in situ hybridization. Histochemistry. 101:1994;303-310.
26. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 66:1975;188-193.
27. Hopf U, Moller B, Stemerowicz R, Lobeck H, Rodloff A, Freudenberg M, et al. Relation between Escherichia coli R (rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet. ii:1989;1419-1422.
28. Freudenberg MA, Kleine B, Galanos C. The fate of lipopolysaccharide in rats: evidence for chemical alteration in the molecule. Rev Infect Dis. 6:1984;483-487.
29. Weisner RH, LaRusso NF, Ludwig J, Dickson ER. Comparison of the clinicopathological features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology. 88:1985;108-114.
30. James SP, Hoofnagle JH, Strober W, Jones EA. Primary biliary cirrhosis: a model of autoimmune disease. Ann Intern Med. 99:1983;500-512.
31. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology. 15:1992;567-571.
32. Desmet VJ, Geber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1994;1513-1520.
33. Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A, et al. Hepatic bile duct injuries in chronic hepatitis C: histopathologic and immunohistochemical studies. Mod Pathol. 7:1994;937-945.
34. Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, et al. Immunomodulatory effect of ursodeoxycholic acid on immune responses. Hepatology. 16:1992;358-364.
35. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis; effect of ursodeoxycholic acid. Hepatology. 11:1990;12-15.
36. Schwarzenberg SJ, Bundy M. Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats. Pediatr Res. 35:1994;214-217.
37. Hori Y, Ohyanagi H. Protective effect of the intravenous administration of ursodeoxycholic acid against endotoxemia in rats with obstructive jaundice. Surg Today. 27:1997;140-144.